Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way and accessories therefor, e.g. filling or cleaning devices, arm rests (A61M5)

A   Human necessities(312083)
A61M5                 Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; accessories therefor, e.g. filling or cleaning devices, arm rests (tube connectors, tube couplings, valves or branch units, specially adapted for medical use a61m0039000000; containers specially adapted for medical or pharmaceutical purposes a61j0001000000)(1768)
A61M5/142 - (93)
A61M5/145 - (32)
A61M5/148 - (4)
A61M5/152 - (6)
A61M5/155 - (3)
A61M5/158 - (42)
A61M5/162 - (3)
A61M5/165 - (4)
A61M5/168 - (41)
A61M5/172 - (11)
A61M5/175 - (1)
A61M5/178 - (93)
A61M5/303 - (2)
A61M5/307 - (3)
A61M5/31 - Details(208)
A61M5/315 - (178)
A61M5/52 - Arm-rests(1)

ethod and system for processing of manual bolus dosing or introduction according to food intake in feedback controllers // 2641976
FIELD: medicine.SUBSTANCE: control system for patients suffering from diabetes mellitus contains an infusion pump, a glucose sensor and a controller receiving signals from at least one glucose sensor and infusion pump. The controller configuration allows calculation of the rate of basal insulin administration and signals to the infusion pump to deliver the amount of insulin determined by the feedback controller using the predictive model based on the desired glucose concentrations in the patient, the amount of insulin administered and the glucose measurement results for the patient. According to the invention, the controller is configured to set the first lower limiting value of insulin infusion if the controller determines that the patient has started manual bolus insulin delivery within the first time period and the glucose concentration is equal to or higher than the first predetermined threshold. The first lower limiting value of insulin infusion is equal to the calculated rate of basal insulin administration. The controller also has the option of setting the second lower restrictive infusion value to 0 if it is determined that the patient has started manual bolus insulin administration within a period of time and the glucose concentration is not more than or equal to the predetermined threshold. Management based on predictive models determines the amount of insulin for delivery based on the first or second lower limiting infusion value. Management based on predictive models is continuously supported by the system. Alternative methods for diabetes control in a patient are disclosed.EFFECT: provided management with regard to food intake and manual bolus administration of insulin.9 cl, 3 dwg

ethod for inguinal hernia treatment // 2641368
FIELD: medicine.SUBSTANCE: in the medial part of the patient's inguinal canal lying on the back, a polymerizable mixture consisting of three solutions A, B and C is introduced by injection through the needle. Solution A is a solution of a copolymer of acrylamide and hydroxysuccinimide ester of acrylic acid. Solution B is a solution of 1,4-butanediamine and succinic acid. Solution C is a solution of sodium hydrogencarbonate. The molar ratio of acrylamide and hydroxysuccinimide ester of acrylic acid in the copolymer is selected in the range of 9:1 to 7:3, the molar ratio of 1,4-butanediamine to succinic acid in solution B is selected in the range of 4:1 to 1:1. The concentration of solution A was selected from the mass concentration of the copolymer in solution A in the range 21.8-26.3 g/l. The concentration of solution B is: for 1,4-butanediamine - about 22.0 g/l, for succinic acid - in the range of 7.4-29.5 g/l. The concentration of solution C is in the range of 0.6-1.1 mol/l. The ratio of the quantity of solutions A and B is chosen so that the molar ratio of hydroxysuccinimide ester of acrylic acid in the copolymer and 1,4-butanediamine does not exceed 2:1. The ratio of the quantity of solutions B and C is selected from the condition that the molar ratio of sodium hydrogencarbonate and succinic acid is not less than 2:1. The mixture is prepared by successively mixing solutions A and B and then solution C. Then, the prepared mixture is injected until the inguinal canal is filled and the patient is left in the indicated position until the polymerization of the mixture introduced into the inguinal channel is completed.EFFECT: invention allows minimally invasive elimination of hernial protrusion, reliable closure of hernial gates, and prevention of recurrent inguinal hernia.7 cl, 9 dwg

Adapter for drug delivery device and method for this adapter installation thereon // 2640946
FIELD: medicine.SUBSTANCE: group of inventions refers to an improved adapter, for example, an adapter with a Luer nozzle, for use with a drug delivery device, and to a drug delivery device having such an improved adapter, to a method for adapter installation on such a drug delivery device and to an assembly, containing such an improved adapter and a connecting element connected to the said adapter. The adapter (10) is intended for installation on the distal tip (2) of the drug delivery device (1). The distal tip has an axial channel (3) to move the drug contained in the drug delivery device. The adapter has a longitudinal axis A aligned on the axial channel. The adapter comprises connecting means (34) to attach the adapter to the connecting element. The adapter further comprises an inner ring (20) configured to be removably engaged on the distal tip and compression means (30, 32) separate from the inner ring and intended for non-removable snapping on the inner ring meshed on the distal tip by proximal movement of the compression means relative to the inner ring. The compression means are adapted to apply a pressure directed towards the center to the inner ring so as to prevent axial movement of the inner ring relative to the distal tip. The inner ring comprises an annular wall (21) adapted to expand outwards radially under pressure applied radially outwards to the inner surface (21c) of the annular wall and configured to be compressed inward radially under pressure applied radially inside on the outer surface (21d) of the annular wall. The compression means comprise an outer ring (30) adapted to receive at least the inner ring at least partially. The outer ring comprises an inner radial rim (32) adapted to apply a pressure directed to the center of the outer surface (21d) of the annular wall (21) when the compression means are latched onto the inner ring. The annular wall (21) has a longitudinal slot (23) along a portion of its circumference. The longitudinal slot extends from the proximal end to the distal end of the annular wall (21). The drug delivery device (1) comprises a distal tip (2) with an axial passage (3) for moving the drug contained in the said drug delivery device and at least one of the above adapters. The method for installation of the above adapter (10) on the distal tip (2) of the above drug delivery device (1) comprises at least the following steps: the inner ring (20) is slid into the distal tip, the compression means (30) are snapped on the inner ring by proximal displacement of the said compressing means relative to the said inner ring. The assembly includes the above adapter (10) and a connector (40) connected to this adapter.EFFECT: effective and reliable connection between the drug delivery device and the connecting element.14 cl, 7 dwg
Acrylic composition from two parts containing ability to cure // 2640234
FIELD: chemistry.SUBSTANCE: composition comprises the liquid first part stable at storage and the liquid second part stable at storage which react with each other upon mixing with the formation of cement which hardens. The composition further comprises an acrylic monomer component and an amount of an initiator component for polymerizing the monomer component. The monomer component and the initiator component are typically in the separate parts of the two parts of the composition, so that the monomer component is stable at storage. The liquid first part contains, in a liquid carrier, acrylic polymer particles obtained by emulsion polymerization. A method for the preparation of a curable, two-part acrylic composition is also described. The composition is particularly useful when used in a syringe or a compression seal gun having at least two cylinders. A solid cement composition of bone cement, obtained by curing the acrylic composition consisting of two parts is porous and permits controlled release of antibiotics and medicines into the surrounding bone and tissue.EFFECT: low temperature of the exothermic effect during curing, the adhesion of the composition of bone cement that prevents, in particular, tissue necrosis, and the provision of the porous bone cement provides the cement mechanical properties matching the characteristics of the surrounding bone.28 cl, 16 tbl, 79 ex
ethod for multispiral computer tomography-phlebography of lower limbs in case of varicose vein disease // 2638920
FIELD: medicine.SUBSTANCE: invention can be used for diagnosis of violations of venous hemodynamics in patients with chronic venous insufficiency of the lower limbs (LL CVI). Multispiral computer tomography-phlebography of LL in case of varicose vein disease is perfromed, for which subcutaneous veins of the researched LL foot are catheterized with introduction of an x-ray contrast mixture (XRCM). The first stage with simultaneous delayed start from the beginning of XRCM introduction and patient's breathing and the second scannig stage with a delayed start at free breathing are performed subsequently, creating a 3D image of veins with automatic volumetric rendering protocols set in the multispiral computer tomograph (MSCT). At that, before the first scanning begins, cuffs are imposed on the ankle area and the lower third of the thigh, and pressure in the cuff is first raised in the ankle area. After introduction of the calculated volume of XRCM pressure is raised on the thigh as well. After completion of the first scanning stage, pressure in the thigh cuff is reduced to zero and a functional test on the effectiveness of talocrural musculo-venous LL pump operation is performed by conducting five rear bends of the patient's foot. At that, both scanning stages are performed in the direction from the pelvis to the foot.EFFECT: method provides efficient, accurate and physiological (in terms of pressure increase in the venous line while changing the body position) contrast and visualization of not only lower limb veins, but also of the patient's pelvis with the most comprehensive phase contrast progress proximally with determination of degree of limb intramuscular veins ectasia.1 ex

Injection assembly // 2638675
FIELD: medicine.SUBSTANCE: injection assembly comprises a prefilled injetion device including a conjugation tip having a tubular connecting portion for liquid passage, a plug closing a free end of the tubular connecting portion of the conjugation tip, connected by means of a damageable portion with a free end of the tubular connecting portion, and a protecting device which comprises an integral body including a protecting part detachably mounted on the conjugation tip of the injection device so as to at least partially close and protect the mentioned conjugation tip, a connection part connected to the protecting part and having a socket outlet configured to interact with the plug, and a bearing part connected to the connection part, and an injection element which in the storage position detachably mounted on the bearing part, wherein the injection element comprises and injection needle and a connecting tip, connected to allow liquid passage with the injection needle, wherein the connecting tip can be mounted on the conjugation tip of the injection device in the using position of the injection element, wherein the injection element and the bearing part are made in such a way that in the storage position of the injection element the connecting tip can interact with the conjugation tip.EFFECT: invention provides an easy installation of the injection needle and limits the contamination risk of the conjugation tip of the injection device or injection needle.11 cl, 14 dwg

Auxiliary device for connection to injection device // 2638620
FIELD: medicine.SUBSTANCE: device contains: the main body; a device to support the main body of the auxiliary device in a predetermined mutual arrangement with the injection device; a transparent protective window located on the surface of the main body, which, when used, is aligned with the dosage window of the injector syringe; and a sensing device supported in the main body and comprising a sensor directed to the protective window. The protective window has optical power. The protective window can be a cylindrical lens or a toric lens.EFFECT: reduced cushion-like distortion with provision of compact dimensions.28 cl, 19 dwg

Nozzle for syringe, carpule or similar device // 2638617
FIELD: medicine.SUBSTANCE: invention relates to a nozzle for a syringe or a carpule containing a main body surrounding an interior space into which a protrusion of a syringe or carpule can be inserted, the main body has a an interior space surrounding shell and an inner body with an inner wall connected to the shell and coaxial therwith, the inner wall faces the interior space with its inner surface, in the put-on state of the nozzle it is adjacent to the outer surface of the syringe or carpule protrusion. This nozzle is characterized by the inner wall of the inner body connected to the nozzle shell by a plurality of bridges, at least one bridge forms an angle with an imaginary radially extending line α, which is greater than 0° and is an acute angle.EFFECT: increased convenience.15 cl, 4 dwg

Drug introduction with pressure measurement of and intermittent flow for identification of fluid-filled anatomical spaces and injection provision therein // 2638449
FIELD: medicine.SUBSTANCE: space can take fluid at a pressure less than the pressure of tissues. The device contains a unit of disposable elements. The unit comprises a syringe having a main body for the fluid to be injected into the anatomical space. The syringe comprises a piston configured to move at one end of the main body to dispense fluid from the opposite end of the main body. The assembly includes tubes that are integrally connected to the opposite end of the main body. The assembly includes a needle connected to the tubes and having a tip adapted to be inserted into the patient and moved through tissues surrounding the anatomical space to search for this anatomical space. The unit includes a built-in electronic pressure transducer between the opposite end of the main body and one end of the tubes, to generate a signal corresponding to the instantaneous pressure at the tip of the needle. The apparatus comprises a drive unit connected to the syringe and electronic pressure transducer. The unit contains a control device with a computer. The unit comprises a memory to store the first selected pressure (P1) corresponding to fluid injection into the anatomical space. The unit includes an engine connected to and controlled by the computer. The unit comprises a syringe valve connected to the engine with a syringe to move the piston into and out of the main body for injection and aspiration of the fluid from the anatomical space. The computer is programmed to control the engine to move the piston to provide a discontinuous flow of fluid to the patient until the first selected pressure (P1) is detected by the electronic pressure transducer. The engine stops working to stop the flow of additional fluid to the patient until the instantaneous pressure at the tip of the needle decreases to a value less than the first selected pressure. The program resumes engine operation to resume the flow of fluid to the patient while the needle is moving in the patient's tissues. The flow of fluid in the tissue stops at the instantaneous pressure exceeding the first selected pressure (P1), and resumes when the instantaneous pressure decreases to a value less than the first selected pressure to alert about the needle tip being in the anatomical space and for eventual resumption of fluid injection into the specified anatomical space. The storage device stores the second selected pressure (P2), the value of which is less than the value of the first selected pressure (P1) by the first selected value. The computer is programmed with a possibility of resuming the engine operation to resume piston movement, ensuring the resumption of the fluid flow to the tip of the needle when the instantaneous pressure is less than the value of the first selected pressure (P1) by the first selected value.EFFECT: increased reliability and safety of epidural injection by limiting the volume of fluid to determine the epidural space.17 cl, 10 dwg
ethod for diagnostics of inflammatory process in lungs and in intrathoracic lymph nodes in patients with sarcoidosis // 2638447
FIELD: medicine.SUBSTANCE: invention concerns determination of severity and prevalence of inflammation in lungs and intrathoracic lymph nodes (ITLN) in patients with sarcoidosis. Radiopharmpreparation (RPP) 99mTc-tehnetril is injected and x-ray study is carried out assessing the severity of RPP accumulation and its topical localization in the lungs and ITLN. At that, the RPP is obtained before the introduction, as follows: technetium-99m is injected into a vial with technetril lyophilisate after elution, placed in a lead container and heated on a water bath for 15 min since water boils at the level of the water in the bath above the level of solution in the vial, cooled to room temperature. After RPP introduction upon reaching its energy peak, gamma-scintigraphy and/or single-photon emission tomography of the lungs and ITLN is performed, defining the extent and prevalence of pathological process in the lungs and ITLN by calculation of RPP absorption index in the inflammation focus. Its value from 10% to 20% above the background values is considered normal - zero degree, from 21% to 30% - mild, from 31% to 40% - moderate, and over 41% - pronounced pathological inclusion of RPP.EFFECT: method provides high safety and promptness of diagnosis, accuracy of expression and prevalence of the inflammatory process in the lungs and intrathoracic lymph nodes, irrespective of the radiographic data, an objective assessment of metabolic and inflammatory processes.4 dwg, 1 ex
ethod for treatment of teeth hyperesthesia in patients on background of somatic diseases // 2638293
FIELD: medicine.SUBSTANCE: after a professional hygienic cleaning of teeth, 1.0-2.0 ml of "R.O.C.S® Medical Minerals" gel is applied on all surfaces of the teeth enamel with a circular brush. After that, 1.0-1.5 ml of "Gialudent gel" No.3 is applied to the mucous membrane of the teeth gums, isolated from saliva, with a disposable application syringe. Laser therapy is carried out by a laser semiconductor dental therapeutical device "Optodan" with a periodontal nozzle, in frequency mode II, with exposure of 1 minute per 4 fields of the left and right halves of both jaws, no more than 4 minutes for 1 procedure. The therapeutic course makes 7-10 daily procedures. Additionally, a vitamin-mineral complex of chewable tablets "R.O.C.S Medical" is administered 1 tablet 3 times a day for 30 days.EFFECT: decreased prevalence, intensity of tooth hyperesthesia and caries intensity, increased enamel resistance with long-term and persistent effect of remineralization and stabilization of enamel zones demineralization.3 tbl, 6 ex

Drug delivery device // 2638274
FIELD: medicine.SUBSTANCE: device contains a body. The body is arranged to accommodate a drug container, a drive unit located to influence the drug container locate in the housing to displace a drug dose. The drive unit comprises a plunger rod and a power member operatively associated with the plunger rod for driving the plunger rod to displace the drug dose, a connector provided with retention elements cooperatively releasable with a plunger rod for retention with a possibility to release the plunger rod, an actuating member configured to axially move relative to the retention elements from the locked position to a released position, a manually operated actuator configured to axially move relative to the housing and operatively associated with the actuator. The actuator is arranged to move the actuator from the locked position to the released position during operation, a safety device comprising safety elements located to be movable between the locking position and the unlocking position of the actuator. In the locking position, unintentional release of the plunger rod is prevented and the manually operated activator operatively associated with the safety device for moving the safety elements from the locking position to the unlocking position during operation.EFFECT: increased application convenience.8 cl, 11 dwg

ethod for mini-access planning for creation of extra-intracranial microanastomosis with application of brain msct-angiography in 3d reconstruction // 2637826
FIELD: medicine.SUBSTANCE: in the planning of mini-access for creation of extra-intracranial microanastomosis, brain MSCT-angiography in 3D reconstruction is used. At that, mini-access is performed through a cutaneous incision in the projection of the superficial temporal artery (STA) branch, which is determined in the three-dimensional image in the visualization program and has a minimum distance to the recipient artery optimal in size and localization. Incision line is marked in 3D reconstruction by measuring the distance from the point of intersection of the main trunk or the parietal STA branch with the zygomatic arch to the chosen access point, which is located in the middle of the access.EFFECT: increased accuracy of mini-access planning with access to the recipient artery, which may be the middle cerebral artery, as well as reduced operation time, reduced tissue trauma, reduced blood loss, better cosmetic effect, with complete exception of marginal wound necrosis formation, method simplification with application of available software.13 dwg, 1 ex

edical and pharmaceutical fluid container // 2637615
FIELD: medicine.SUBSTANCE: container for insulin preparation storage comprises a liquid storage compartment containing an outlet opening. The container has a porous hydrophilic membrane layer located inside the fluid storage compartment. The hydrophilic membrane layer is gastight in the wet state, and at least covers the outlet opening sealing its periphery and is configured to exclude gas passage at the maximum pressure exerted by the dispensing system, and to prevent a negative effect on the insulin preparation. The thickness of the hydrophilic membrane layer is between 50 and 300 mcm, and the pore sizes are in the range of 0.2-1.0 mcm.EFFECT: container reliability increase.15 cl, 8 dwg

Stopping mechanism for drug delivery device // 2637173
FIELD: medicine.SUBSTANCE: automated injector comprises a syringe carrier and is configured to contain a syringe. The syringe carrier has a bevel element with the first bevel and the second bevel. The automated injector includes a main body including an elastic bar having a bar head, adapted to engage the bevel element. The first bevel is configured to deflect the bar head radially relative to the main body, and the second bevel is configured to deflect the bar head in a tangential direction relative to the main body.EFFECT: improved mechanism.16 cl, 25 dwg

Adapter for device of needleless access and method for connection of this device with this adapter // 2636197
FIELD: medicine.SUBSTANCE: invention relates to an adapter for connection of a drug delivery device to a needleless access device provided with a straight external thread comprising a coupling means to mount the said adapter on a drug delivery device and an internal thread adapted to interact with the said external thread at a predetermined length L. At that, the said internal thread has, at the distal portion of the said extension L, an outer diameter D1 interfaced to the outer diameter of the said straight external thread, adapter differs by its internal thread having an outer diameter D2 at the proximal portion of the said length L, wherein D2 diameter is strictly smaller than D1, and wherein the said internal thread further comprises a tapered portion connecting the said proximal portion to the said distal portion. The invention also relates to a drug delivery device comprising such an adapter, and methods for connection of a needleless access device to an adapter, and also to a drug delivery device.EFFECT: device improvement.13 cl, 4 dwg
ethod for optic nerve atrophy treatment after craniocerebral injury // 2635485
FIELD: medicine.SUBSTANCE: when treating optic nerve atrophy after a craniocerebral injury, 1000 mg of Recognan in 4 ml of 0.9% saline is injected intravenously once a day. In addition, from the first day of treatment, 10 sessions of endonasal electrophoresis are performed from the negative pole for 20 min with 10 mg of chymotrypsin, diluted in 5 ml of 0.2% saline. The course of treatment is 10 days.EFFECT: method provides stabilization of visual functions while reducing the pharmacological load on the body, long term effect, absence of complications associated with the central nervous system.2 ex

Device for drug delivery // 2635484
FIELD: medicine.SUBSTANCE: device contains: a syringe with a body from which a needle extends; an inner casing adapted to move between a retracted position in which the needle projects beyond the distal end of the inner casing and an extended position in which the needle is covered by the inner casing; a support casing configured to hold the body, and also to hold the inner casing in retracted and extended position; a piston rod comprising a piston, wherein the piston rod can be moved from the first position in which the piston rod is withdrawn to the second position in which the drug delivery process is completed, as well as an actuating head. In this case, the actuating head is attached at the proximal end of the piston rod. The support housing comprises a proximal section, the proximal section of the support housing and the actuating head comprising respective indicators providing visual feedback when the piston rod is in the second position. The corresponding indicators are made in the form of coloured marks. The marks are formed as: fragmented marks, the actuating head and the supporting casing correspondingly comprise a plurality of fragmented marks or material colouring, wherein the support casing material is at least sectionally is coloured translucent material or transparent material. The degree of transparency or colour of the translucent material of the support casing substantially corresponds to the degree of transparency or colour of the material of the actuating head.EFFECT: use of the invention provides feedback on the position of the piston rod after full delivery of the drug substance.18 cl, 16 dwg
Filtration systems and methods for filtration of particles of predetermined substance // 2635180
FIELD: medicine.SUBSTANCE: filtration system comprises a filter medium containing several holes defined therein, and a group of microcolumns, each being in line with one of the several holes, and is configured to be repelled by particles of a predetermined substance involved in a fluid flow directed through the filtration system. A method for filtration of particles involved in the fluid flow and a structural version of the filtration system are disclosed.EFFECT: filtering of similar particles is provided.20 cl, 5 dwg
ethod for complex treatment of endogenous uveitis followed by macular edema // 2635083
FIELD: medicine.SUBSTANCE: alternately, on the side of the affected eye, pterygopalatine and BTE drug injections are performed and ultraviolet irradiation of blood is performed. Pterygopalatine injections are performed by introducing platelet-enriched autoplasma at a dose of 3-5 ml by a course of 3-4 injections with an interval of 72-96 hours. BTE injections are performed by administering a drug mixture containing dalargin 1 mg, lidocaine 40 mg, mexidol 50 mg, gemaza 5000 ME. The course of treatment is 6-7 injections daily. In addition, an intravenous injection of ozonized saline with an ozone concentration of 400-800 mcg/l, volume of 150-200 ml, at a rate of 30-40 drops per minute, with a course of 6-7 injections, is performed daily.EFFECT: persistent long-term clinical outcome, consisting in improved visual functions, increased visual acuity due to relief of inflammation in the uveal tract.3 cl, 6 dwg, 3 ex
ethod for intestine peristalsis stimulation in complex treatment of abdominal infection // 2634630
FIELD: medicine.SUBSTANCE: intraportal administration of ozonized saline and perfluorane is performed. At that, after peritonitis source removal, nasointestinal intubation, lavage and abdominal cavity drainage prior to medium wound suturing, recanalization and catheterization of the umbilical vein are performed. Then, on day 1-3 after the operation, intraportal infusion of serotonin adipate is additionally performed by 40 drops per minute at a dose of 20-30 to 40-60 mg/day, depending on the phase of pathological process development and the severity of patient's condition.EFFECT: increased clinical efficacy of intestinal peristalsis stimulation.6 tbl, 1 ex
ethod for preventing postinfarction cardiac remodeling in experiment // 2634375
FIELD: medicine.SUBSTANCE: method comprises dressing the upper third of the left coronary artery and administering the Alloplant biopreparation into the stenosed artery circulation. The administration is carried out by intramyocardial injection of 3.0 mg of a biopreparation diluted in physiological saline. Injections are performed immediately after stenosing the artery at 6 points, by 0.5 mg each.EFFECT: effective stimulation of endogenous mechanisms of myocardial regeneration, preventing postinfarction cardiac remodeling.2 tbl, 1 ex

Cartridge for fluid supply to transmermal drug delivery device (versions) // 2633228
FIELD: medicine.SUBSTANCE: cartridge for fluid supply to the transdermal drug delivery device comprises a casing that at least partially forms an internal space for storage of the fluid to be delivered by the transdermal drug delivery device, the first and second openings into the inner space of the casing, a self-sealing element that at least partially covers the first opening, and a movable member that at least partially covers the second opening. At that, the first and second openings are located adjacent to the opposite first and second ends of the casing, respectively. At least a portion of the movable member is configured to be pushed into the inner space of the casing to increase the pressure in its inner space. According to the second version, the cartridge for fluid supply to the transdermal drug delivery device comprises a casing comprising a substantially concave wall. The substantially concave wall at least partially forms an inner space of the casing for storage of the fluid to be delivered by the transdermal drug delivery device. In the casing, opposite first and second openings are formed at least partially into the inner space of the casing. The second opening is located adjacent to the substantially concave wall. The cartridge also comprises a self-sealing element that at least partially covers the first opening and a deformable member that at least partially covers the second opening. The deformable element is designed to be pushed into the inner space of the casing and at least partially adheres to the concave wall to increase the pressure in the interior of the casing.EFFECT: cartridges provide a new balance of properties of transdermal drug delivery devices.30 cl, 24 dwg
ethod for automatic parenteral administration of pharmaceuticals and blood sampling // 2632762
FIELD: pharmacology.SUBSTANCE: device for automatic administration of pharmaceuticals and blood sampling is mounted on the arm, or the hand is inserted therein. By means of moving the device mounting plate and rotating the lower and the upper device discs, the device is oriented by two axes. A suitable vein or a blood vessel for carrying out the injection is determined. The device is oriented so that the location for a future injection is in the middle of the vessel or the vein. At the time of finding a suitable vessel or vein, cassettes with needles and a cartridge are fixed above a suitable area. Cryo-anestheticis is fed via the channel and sprayed onto the skin surface before carrying out the injection. The cassette needles are introduced into the lumen of the vessel or the vein, and medicinal product supplying or blood sampling is performed.EFFECT: method allows to achieve the painless procedure of the pharmaceutical administration, to provide the possibility of pre-anesthesia, to increase the accuracy of the needle entering the vein lumen.9 dwg
ethod for treating knee osteoarthrosis deformans // 2632621
FIELD: medicine.SUBSTANCE: at the first treatment session, a mixture containing 1 ml of diprospan suspension and 2 ml of a 2% lidocaine solution is injected into the tender points in the projection of the medial meniscus of knee joint which are determined by palpation. 3 ml of the mixture is divided into the identified tender points and injected into the points in equal amounts. After the mixture is injected, acupuncture is performed at points Rp 9, Rp 10, E 36 with steel needles for 20 minutes. At the second session, 2.2 ml of Traumeel C preparation is injected into the tender points in the projection of the medial meniscus of knee joint, which are divided in equal amounts into the number of detected tender points, and then this acupuncture is performed.EFFECT: reduction of treatment time due to rapid relief of pain syndrome, inflammatory phenomena, improvement of trophism of tissues and normalization of blood circulation in the area of the affected limb and increase in functional activity in the affected joints.5 cl, 2 ex
Needle cap // 2632530
FIELD: medicine.SUBSTANCE: inventions relate to a needle cap for use in a medical device to close the medical device needle tip after medical device application, to prevent accidental pricking, for example, of a medical practitioner with the needle tip after needle removal from the medical device, and also to a catheter device containing such a cap. The needle cap (26) for use in the medical device comprises a main body (44), the first and second arms (46, 48) and a stop member (38). The main body (44) is made of the first material and comprises a needle passage (56) extending axially from the proximal side (58) of the body (44) through the body (44) to the distal side (60) of the body (44) for movable accommodation of a needle bar (28) having a large outer profile. The first and second arms (46, 48) extend substantially in the said axial direction (A) from the distal side (60) of the main body (44). The first arm (46) comprises a distal region (62), a proximal region (64) and a distal wall (50) located transversely at the distal area (62) of the first arm (46). The stop member (38) is slidably arranged on the needle bar (28) and is movable relative to the main body (44). The stop member (38) is located in a receptacle (88) formed by a recess or cavity, or chamber in the body portion (44), the axial dimension of the receptacle (88) being greater than the length of the stop member (38), so that the stop member (38) can freely move along the needle bar (28) inside the receptacle (88). The catheter device (40) comprises a catheter tube (14); a cannula (12) catheter; a needle (20) and the above-mentioned needle cap (26). The needle (20) comprises a needle tip (30) and a needle bar (28). The needle bar (28) comprises a distal section (34) and a proximal section (36). At least the proximal section (36) has a large external profile. The needle bar (28) comprises a thickening (32) between the distal section (34) and the proximal section (36). The thickening (32) has an enlarged external profile that is larger than the maximum profile size of the needle channel (56) and/or the stop member (38).EFFECT: invention discloses a cap with improved protective function.12 cl, 4 dwg
Implantable fastener // 2632524
FIELD: medicine.SUBSTANCE: implantable fastener comprises a proximal stabilizing member extending from the proximal end to the distal end, a distal stabilizing member extending from the proximal end to the distal end, a bridge extending from the distal end of the proximal stabilizing member to the proximal end of the distal stabilizing member and a positioning arm extending from the proximal end of the distal stabilizing member. The proximal and distal stabilizing members have a compressed configuration and are configured for transition to a deployed configuration. The deployment system for fastener transdermal delivery and implantation comprises an input device cannula, a pusher and a sheath. The method for deployment system application comprises the following steps: cannula moving towards the target site, fastener positioning in the target region, application of a controlled force to release the first stabilizing member from the compressed state, application of a controlled force to release the second stabilizing member from the compressed state, and cannula extraction. The method for fastener manufacture consists of: material placement on the core, coating of the core with a core coating and heat treatment of the said material to form the said fastener. The core for fastener manufacture comprises the first disc, the second disc and a shaft disposed between the first and the second discs. The first disc has a surface convex towards the second disc, the second disc has a surface convex towards the first disc, each disc has a groove extending from the shaft.EFFECT: possibility to install the fastener in the target location of the patient's body by application of a controlled force, a possibility of implantation into a living animal or human body to control various physiological states.28 cl, 34 dwg
iniature portable multifunctional injection device // 2632511
FIELD: medicine.SUBSTANCE: device contains a vial of liquid and a box-shaped membrane body attached to the supporting frame. The box-shaped membrane body is suitably equipped with a directional input interface and a directional output interface in fluid communication with the vial of liquid and needle via an infusion tube. An elastic membrane is installed in the box-shaped membrane body, and the transmission system is located on the elastic membrane side. The transmission system comprises a miniature DC motor connected to a frequency modulation system. A miniature DC motor is connected to a spiral rectifying device by means of a speed reducer and the spiral rectifying device is connected to the device for membrane reciprocating movement by means of a two-stage shaft. A truncated cone at the front end of the device for membrane reciprocating motion is in contact with the elastic membrane. In the infusion device, the miniaturized DC motor drives the transmission system to allow motion of the device of membrane reciprocating movement, thereby implementing electrical energy conversion to mechanical energy, and implementing the infusion rate adjustment by changing the volume using the device of membrane reciprocating movement compressing the box-shaped membrane body.EFFECT: reduced device size, increased usability.10 cl, 6 dwg

ethod for treating nonscarring alopecia // 2631642
FIELD: medicine.SUBSTANCE: method is based on the administration of mesenchymal stem cells into the mesodermal skin layer. These cells are isolated from the skin biopsy from the scalp of an adult donor. The mesenchymal stem cells are additionally isolated from the placenta. After that, the mentioned cells are mixed in a ratio from 3:1 to 1:3, the volume of the mixture is brought to 2-4 ml. This mixture is administered into the mesodermal skin layer in the alopecia area to a depth of 2-3 mm every 2-3 mm at a volume of each injection equal to 0.02 ml.EFFECT: increased efficiency of treatment.1 ex, 1 tbl, 1 dwg

Injection pen syringe type device and electronic attachment module for this device // 2631213
FIELD: medicine.SUBSTANCE: auxiliary device contains: main part with a front end and a rear end; and a connecting node configured with an ability of detached installation of the main part on the injection device in a specific position relative to the outer surface of the injection device. At that, the connecting node contains a sleeve, continued from the front end of the main part at an acute angle to the longitudinal axis of the main part that is configured to host the injection device so that the injection device continues through the sleeve and the sleeve has a hole; an engaging node configured to engage the auxiliary device with the injection device; and the first and second installation surfaces located apart from each other to accommodate the injection device between them, at that, the first and the second installation surfaces are shifted. The sleeve is configured to rotate about the axis extending perpendicularly to the major axis of the hole between the first position in which the injection device can be disposed by shearing through the sleeve, and the fixed position in which the first and second mounting surfaces are located closely to the external surface of the injection device and are positioned so that no part of the first mounting surface is directly in front of the second mounting surface when it is in the fixed position. At that, the engaging unit is adapted to engage with the injection device when the sleeve is rotated to the fixed position.EFFECT: improvement of the device.14 cl, 20 dwg

Piston for cartridge used in drug delivery device // 2631207
FIELD: medicine.SUBSTANCE: piston contains the first element and the second element. The first element consists of the first material and forms the distal end surface of the piston. The second element consists of the second material that has a lower compressibility compared to the first material. The second piston element is located in the cup-shaped receptacle of the first element and provides a force receiving surface from the proximal end of the piston.EFFECT: improved operation reliability.10 cl, 3 dwg
Transdermal delivery of high-binded bioactive agents // 2630610
FIELD: medicine.SUBSTANCE: device contains a microneedle and multiple nanostructures produced on its surface. They are arranged in a given pattern that provides nanotopography, which, by interacting with surrounding tissues, facilitates high-viscosity composition transportation through the dermal barrier. The device also comprises a fluidly communicating composition comprising a bioactive agent and having a viscosity greater than about 5 centipoise. A method for bioactive agent delivery includes penetration through the stratum corneum with a micro-needule of the claimed device and provision of conditions for composition transportation through the microneedle at a rate above about 0.4 mg/h/cm2 depending on the microneedle surface area.EFFECT: high-viscosity therapeutic composition delivery through the dermal barrier.12 cl, 3 ex, 3 tbl, 34 dwg

Cartridge holder and handle syringe // 2630597
FIELD: medicine.SUBSTANCE: holder comprises a snap fastening connection means for securing the cartridge holder to the drug delivery device body. The fastening connection means is provided with at least one generally rectangular window for fixing member receiving. Each of the corners of the window is equipped with a circular contour like a notch. In each of the corners, on the one circumferential side of the window, the first notches are provided extending in the circumferential direction, and in the corners on the opposite circumferential side of the window the second notches are provided extending axially relative to the longitudinal axis of the cartridge holder.EFFECT: reduced critical peak stresses in the angle zone at low temperatures.7 cl, 9 dwg
ethod for correcting age-related changes in face and/or body soft tissues // 2629527
FIELD: medicine.SUBSTANCE: for correction, a course of three procedures is performed, including the introduction of thrombocytic autoplasm (TAP) into tissues. Before each procedure, sampling of blood in a volume of 9-36 ml is performed, which is centrifuged to obtain a native form of TAP. In carrying out the first two procedures 4 ml of the obtained native TAP form are taken into 4 sterile syringes by 1 ml in each syringe and placed in a thermostat at a temperature of 56°C and exposure for 5 minutes to obtain a fibrin form of TAP. The fibrin TAP form is mixed with 4 ml of native TAP form through the connector, connecting each syringe with the fibrin TAP form to the syringe with the native TAP form and making 5-10 passes from one syringe to the other. The resulting mixture is introduced into the upper layer of the dermis with a needle with a diametre of 30G and a size of 0.3×12 mm or with a cannula with a diametre of 2×5G and a length of 50 mm by papular, tubercular, linear-retrograde, fanning or bolus techniques of mesotherapy. When carrying out the third procedure 4 ml of the native TAP form is taken into 4 sterile syringes by 1 ml in each syringe and placed in a thermostat at a temperature of 75-80°C and exposure for 10 minutes to obtain a protein form of TAP. After cooling for 2 minutes, syringes with the protein TAP form are connected by a connector with an empty syringe and 10-15 passes are made from the syringe with a protein form into each empty syringe and back. The mixture is introduced into the deep layers of the dermis, the hypodermis and the periosteum by means of a cannula with a diametre of 22G and a length of 57 mm by linear-retrograde, fanning or bolus technique. If necessary, the course is repeated 2 weeks after.EFFECT: increased efficiency.4 cl, 2 ex

Device for controlling the temperature of the patient's body // 2629243
FIELD: medicine.SUBSTANCE: device for controlling or supporting the patient temperature control by fluid infusion comprises an infusion fluid supply element; body temperature input configured to receive the actual body temperature of the patient; additional input, adapted to receive an additional parameter representing the actual physiological state of the patient; control unit associated with the input of body temperature and additional input. The actuator controls the actual flow rate and/or the actual temperature of the infusion fluid in accordance with the control signal of the control unit. The control unit controls the temperature of the patient by means of an actuator based on the target body temperature, the actual temperature and/or the set temperature of the infusion fluid, the actual body temperature, the actual flow rate and an additional parameter that includes changing the heart rate.EFFECT: providing control and regulation of patient's body temperature.16 cl, 8 dwg

Injector for fluid injection into human or animal body and method to control this injector // 2628647
FIELD: medicine.SUBSTANCE: injector for fluid injection into a human or animal body comprises a pump for fluid supply at a certain flow rate, a control device to control the pump and establish the desired fluid flow rate, and a pressure measuring device connected to the control device to measuring the pressure of fluid supplied by the pump. The required amount of pumped fluid pressure is predetermined in the control device and the control device is designed to compare the fluid pressure measured by the pressure measuring device to the desired value of the pump fluid pressure, with a possibility of integration, in the event that the necessary pressure is exceeded in some time interval of the function of dependence on pressure time measured by the pressure measuring device. The control device also has a possibility of integration of pressure difference between the pressure measured by the pressure measuring device and the desired pressure of the fluid supplied by the pump, over this time interval to obtain the pressure integral value. The control device disconnects the pump or reduces its power if the resulting pressure integral value exceeds the predetermined limit value of the integral. A method to control the injector for fluid injection is disclosed.EFFECT: inventions allow to increase safety by preventing excess of dangerous pressure in the injection system and excluding extension of the injection process due to decreased power.18 cl, 4 dwg

Improved stretch elastomer pump for the infusion system // 2628062
FIELD: medicine.SUBSTANCE: elastomeric pump for the infusion unit contains a central rod with a cylindrical body and a stretchable elastomeric tube. The cylindrical body has a first end and an opposing second end, a length, a constant outer diameter defining the first radius, a central channel extending along the entire length of the rod, a first port located between the first end and the second end and extending from the outer diameter to the central channel, for the fluid, a fill port located at the first end and communicating with mentioned channel and an output port located at the second end and communicating with mentioned channel. A stretchable elastomeric tube is disposed around a central rod between its first and second ends and coaxially with the overlapping of the first port. The tube is sealed to the central rod at its ends and has an initial internal diameter defining a second radius corresponding to the first radius, length, which is less than the length of the central rod, and the wall thickness, chosen taking into account the second radius. The variants of performing the pump, differing in the characteristics of the elastomeric tube, are disclosed.EFFECT: providing long-term outpatient administration of pharmaceutical fluids at a controlled rate.14 cl, 8 dwg, 11 tbl

Auxiliary device for fastening on injection device // 2628052
FIELD: medicine.SUBSTANCE: auxiliary device contains a dose window that closes the sleeve, where the dose values are marked. The auxiliary device also comprises a main body; a device to support the main body of the auxiliary device in a predetermined position relative to the injection device; a transparent protective window located on the main body surface that is aligned with the dose window of the injection syringe pen while used; a sensor device installed in the main body and containing a sensor directed to the protective window; an illumination device comprising one or more light sources. Each of one or more light sources is directed to the protective window; and the non-transmissive part located on the optical path between the first of one or more light sources and a point on the dose window where the reflection to the sensor will occur.EFFECT: improvement of the device.18 cl, 19 dwg

Syringe system and piston device // 2627676
FIELD: medicine.SUBSTANCE: syringe system contains a syringe body and a limiter. The syringe body comprises a hollow cavity, a proximal open end and a distal end. The syringe body is configured to contain liquid. The limiter is located in the hollow cavity of the syringe body and forms a seal with the inner wall of the syringe body. The limiter is configured to slide within the hollow cavity to facilitate movement of fluid within the syringe body. The limiter comprises a base and one or more gripping elements extending in a backward direction from the base. At that, one or more gripping elements, each, contains a chamfered edge. The chamfered edge is configured to interact with the plunger of the fluid delivery device to deflect one or more gripping elements in the radial direction when the limiter rotates relative to the plunger to facilitate limiter removal from the plunger. The piston device includes a limiter configured to slide within the hollow cavity of the syringe to facilitate fluid movement within the syringe. The limiter comprises a base and one or more gripping elements extending in a backward direction from the base. At that, one or more gripping elements, each, contains a chamfered edge. The chamfered edge is configured to interact with the plunger of the fluid delivery device to deflect one or more gripping elements in the radial direction when the limiter rotates relative to the plunger to facilitate limiter removal from the plunger.EFFECT: inventions provide simple detachment and attachment of a syringe plunger part to the limiter part using a connector, which allows the same injector to be used for a variety of other syringes; in addition, the inventions provide a quick and simple solution for health care providers, since the plunger can be inserted and connected to the limiter without special orientation.24 cl, 11 dwg

edical device, containing lighting apparatus // 2627635
FIELD: medicine.SUBSTANCE: device for patient intradermal or subcutaneous treatment comprises a piercing element for penetration of a patient's skin site; a lighting apparatus for piercing element illumination and/or for skin site illumination before and/or during treatment procedures, wherein the lighting apparatus is further configured to visually indicate a predetermined course of action in the treatment procedure.EFFECT: group of inventions allows to increase procedure convenience and safety by providing a relationship between the lighting apparatus operating mode and the prescribed sequence of injection procedure.17 cl, 5 dwg

Needle-free intradermal injection device // 2627632
FIELD: medicine.SUBSTANCE: needle-free injection device includes a main spring that can be compressed using one or more handles. Handles are attached to the device for bringing the needle-free injection device to the cocked position. The injector tube and the corresponding devices move relative to other device designs when the injector is pressed against the patient's skin with sufficient force.EFFECT: operative switches and unlocking mechanisms cooperate to prevent injection until the device is properly positioned for injection.20 cl, 18 dwg

Improved device for dosage adjustment with restrictive mechanism for product delivery device // 2627622
FIELD: medicine.SUBSTANCE: device comprises the first and the second limiting means with the first and the second locking means, respectively. Moreover, the second restricting means follows the movements of the first restricting means during metering movement with a predetermined gear ratio. Moreover, the second restricting means does not move relative to the first restricting means during the delivery process. Each of the first and second locking means follows a curvilinear trajectory as it moves so that the two curvilinear paths intersect at least in one point or run close to each other, so that the stop means contact each other in the locking position, at that, blocking of restrictive means movement relative to each other during the dosing process. At that, the respective curvilinear trajectories drawn by the first and the second locking means are closed and can be traversed, preferably several times, by the first locking means, the second locking means, or both, until the locking means contact each other in the locking position.EFFECT: improvement of the device.17 cl, 23 dwg

Injection apparatus // 2626143
FIELD: medicine.SUBSTANCE: injection apparatus comprises a housing where a receptacle for a reservoir with injected liquid is provided. At that, the injection apparatus has a control for injection dose setting. The injection apparatus has a dosing mechanism that is rotatable relative to the body about the central longitudinal axis of the injection apparatus when the injection dose is set. The dosing mechanism has a zero position and at least one injection position. Moreover, no dose value is set in the zero position, and the prescribed dose of injected liquid is set in each injection position. Moreover, the injection apparatus has a fixing device that operates between the delivery part and the housing. The delivery part is rotatable about the central longitudinal axis of the injection device to set the injection dose, whereby during setting of the injection dose, the delivery part is connected without the possibility of relative rotation with the dosing mechanism. In this case, when the dose is squeezed out, it is possible to move the delivery part relative to the housing towards the central longitudinal axis and to direct it to at least one longitudinal edge of the housing. Moreover, at least one fixing element of the fixing device is formed on the longitudinal edge. In this case, each injection position of the dosing mechanism corresponds to the position of fixation of the fixing device. In this case, the metering mechanism is designed to be installed in at least one intermediate position in which no prescribed dose of the injected liquid is set, with a spring provided between the metering mechanism and the housing, which is arranged to return the dosing mechanism from the intermediate position to the injection position, or in the zero position in the absence of influence on the control.EFFECT: improved application convenience.12 cl, 70 dwg
Automated injector for adrenaline injection // 2626132
FIELD: medicine.SUBSTANCE: invention relates to automated injectors such as automated medical injectors, and particularly to rechargeable automated injectors that may be capable of supplying one or more individual doses from a medicament cartridge or a prefilled syringe containing a medicament. The rechargeable automated injector for adrenaline injection has a housing to accommodate a syringe with a needle, a piston rod, piston rod tube, a syringe, an actuator, a piston rod actuator and a recharge mechanism. The syringe is located in the housing for movement between the first position in which the needle is positioned within the housing and a second position in which the needle protrudes outwardly from the housing. The piston rod is made to advance in the syringe to deliver at least one dose of medicament. The piston rod tube has two or more deflectable locking elements provided for engagement with the piston rod stopper for piston rod locking with the piston rod tube in the normal state. The syringe actuator is made for force application to the syringe thereby moving the syringe from the first position to the second position. The syringe actuator is also configured to advance the piston rod tube with the piston rod to the second position. The piston rod actuator is configured to apply force to the piston rod to advance the piston rod in the syringe for delivery of one dose of medicament after each of the two or more deflectable stoppers are released. The recharge mechanism is configured to retract the syringe from the second position to the first position and to recharge the syringe actuator for re-activation of the syringe actuator. The recharge mechanism is configured to release the first deflectable stopper after the first movement of the syringe from the first position to the second position, thus freeing the piston rod from the piston rod tube to supply the first drug dose, and release the other deflectable stopper after another movement of the syringe from the first position to the second position, thereby releasing the piston rod of the piston rod tube to supply another dose of medicament. The recharge mechanism comprising activation of the automatic injector for another injection, requires an operator start-up. The recharge mechanism includes a rechargeable handle with the first hole formed to align with the first deflectable member when the piston rod tube is advanced to the second position for the first time, and another hole formed to align with the other deflectable member when the piston rod tube is advanced to the second position next time.EFFECT: invention provides selective supply of one or more doses, wherein the subsequent doses are also fed automatically, and together with compact dimensions, provides reliability in prevention of premature drug removal, which can lead to wet injection.18 cl, 15 dwg

Tip cap and injection device with distal tip tightly closed by tip cap // 2626127
FIELD: medicine.SUBSTANCE: tip cap comprises the following: a closed distal end portion having a substantially transverse proximal surface; a peripheral skirt extending proximally from the said proximal surface, the said peripheral skirt having an inner surface adapted to interact with the outer surface of the injection device tip; a connecting protrusion protruding from the proximal surface of the distal end portion in the proximal direction and configured to engage the injection device tip. The tip cap inner cavity is formed such that: the outer fillet has a curvature radius of 0.4 to 0.6 mm; the inner fillet has a curvature radius of 0.25 to 0.35 mm; the width of the connecting protrusion base is from 1.4 to 1.6 mm; the domed proximal portion of the connecting protrusion has a curvature radius of 0.55 to 0.70 mm.EFFECT: improvement of the sealing interaction between the cap and the tip of the injection device.11 cl, 19 dwg, 1 tbl

Syringe holder // 2626120
FIELD: medicine.SUBSTANCE: syringe holder comprises a base portion for syringe barrel receiving. The base portion has the first diameter and comprises an expanded distal portion with the second diameter that is larger than the first diameter. The expanded distal portion comprises one or more resilient teeth intended for engagement with a peripheral gap between the syringe barrel and needle protective means covering the syringe needle. The expanded distal portion is adapted to insert the cylindrical tool. The tool has an open end adapted for insertion of the protective means covering the syringe needle. The tool has the third diameter equal to the second diameter. The resilient teeth are adapted to deflect when engaged with the tool to ensure the needle protector distal passage by the teeth. The tool for syringe insertion into the holder comprises a casing for needle protector reception. The tool has the first surface for coupling with one or more resilient teeth when the tool is inserted into the expanded distal portion.EFFECT: group of inventions solves the problem of drug delivery device assembly simplification.5 cl, 48 dwg
Device for injection of diplotic veins of isolated skull cap // 2625652
FIELD: medicine.SUBSTANCE: device for injection of diploic veins of isolated skull cap comprises a container for injection mass, a compressor and a piping system. The inner and outer ellipsoidal compartments are concentrically arranged on the plate. The lower edge of the inner compartment wall is rigidly attached to the plate and is provided with an inflatable cuff, fixed at its upper edge, and the outer compartment contains the removable transparent domed hood, the lower edge of which is placed on the plate in the groove with an elastic seal and fixed by clamps located on its outer perimeter, in addition, there is a vessel in the outer compartment for the injection mass, designed as a elliptical trough with a chamfered bottom located concentrically, and the outer compartment and the inflatable cuff communicate with the compressor by pipimg, the inner compartment communicates with a vacuum pump. The positive effect of the device: catheterization of the diplic veins canals holes, canals veins or emissary veins holes is not performed, which reduces the number of operations and shortens the time for device preparation for work; satisfactory injection of diploid veins is provided.EFFECT: device has a simple design and does not contain expensive parts.4 cl, 3 dwg

Syringe carrier // 2625288
FIELD: medicine.SUBSTANCE: syringe carrier comprises a housing adapted to receive a syringe barrel. The housing includes an annular groove formed at the distal end and adapted to receive the annular lock. The annular lock is located in the circular gap between the syringe barrel and the needle cover covering the syringe needle. The needle cover is removably mounted on the needle. While connected to the needle, the needle cover portion is configured to cover the syringe neck portion, leaving a circular gap between the cylinder and the needle cover.EFFECT: invention solves the problem of drug delivery device assembly simplification.8 cl, 48 dwg
ethod for treatment of primary localized malignant neuroendocrinal tumours of pancreas head // 2625276
FIELD: medicine.SUBSTANCE: invention can find application in treatment of resectable malignant neuroendocrine tumours (NET) of the pancreas head (PH). 5-6 days before radical removal of the tumour, intraarterial oily chemoembolization of the pancreas head vessels is performed using 0.3 mg/kg of doxorubicin in 5-6 ml of lipidol. After surgical removal of the tumour, a dynamic observation of the patient by positron emission tomography (PET) of the whole body with radiopharmaceutical (RP) Ga-68 DOTATATE is performed. When its pathological accumulation in the form of a local recurrent tumour is revealed, it is removed. When NET metastasis is detected, it is either removed or intraarterial oily chemoembolization with doxorubicin in a dose of 0.5-0.7 mg/kg in 5-6 ml of lipidol is carried out, followed by dynamic observation of the patient by means of whole-body PET with Ga-68 DOTATATE. At that, Ga-68 DOTATATE is used at a dose of 1.5 MBq, but not less than 100 MBq per administration.EFFECT: method provides timely antitumor treatment and reduces the possibility of local recurrence.2 cl, 2 ex
ethod for treatment of malignant neuroendocrinal tumours of pancreas head with metastases in liver // 2625275
FIELD: medicine.SUBSTANCE: invention can find application in treatment of malignant neuroendocrine tumours (NET) of the pancreas head (PH). Prior to surgery to remove the primary tumour, selective intraarterial oily chemoembolization of the pancreas head vessels is performed using 0.3 mg/kg of doxorubicin in 6-7 ml of lipidol, of which 1/3 of doxorubicin and 3 ml of lipidol are administered super-selectively into the tumour vessels. Simultaneously, intraarterial oily chemoembolization of blood vessels feeding the liver and NET metastases is performed using 0.4 mg/kg of doxorubicin in 6-7 ml of lipidol. Then, during surgery to remove the primary tumour, radiofrequency ablation (RFA) is also performed in the presence of a single large metastatic lesion or multiple metastases in the liver. After surgery, intraarterial oily chemoembolization of liver metastases is performed, using doxorubicin at a dose of 0.5-0.7 mg/kg in 5-10 ml of lipidol until remission is achieved, under the control of PET with radiopharmaceutical (RP) Ga-68 DOTATATE. If pathological accumulation of RP is detected in the tumour bed at a local relapse or when distant NET metastases are detected, antitumor treatment is conducted. The primary tumour of the pancreas head is removed as a standard pancreatoduodenal resection in isolated neoplasms or in the form of an extended operation with resection of surrounding organs and main vessels, or in the form of extended lymphadenectomy with minimization or absence of surgical influence on intrahepatic metastases. Ga-68 DOTATATE is used at a dose of 1.5 MBq/kg, but not less than 100 MBq per administration.EFFECT: method provides minimization of surgical treatment traumatism at high treatment efficiency.3 cl, 2 ex
 
2551001.
Up!